Ishares Biotechnology Etf Performance
| IBB Etf | USD 138.66 0.21 0.15% |
The etf retains a Market Volatility (i.e., Beta) of 0.48, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, IShares Biotechnology's returns are expected to increase less than the market. However, during the bear market, the loss of holding IShares Biotechnology is expected to be smaller as well.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days iShares Biotechnology ETF has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong fundamental drivers, IShares Biotechnology is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors. ...more
1 | Crestwood Advisors Group LLC Sells 615 Shares of iShares Biotechnology ETF | 11/06/2024 |
2 | Bond Devick Financial Network Inc. Reduces Holdings in iShares Biotechnology ETF | 11/11/2024 |
3 | Should You Invest in the Invesco Biotechnology Genome ETF | 11/20/2024 |
4 | RS Crum Inc. Sells 127 Shares of iShares Biotechnology ETF | 11/27/2024 |
5 | Should You Invest in the iShares Biotechnology ETF | 12/03/2024 |
6 | Is iShares Biotechnology ETF a Strong ETF Right Now | 12/09/2024 |
7 | Altimmune Added to Nasdaq Biotechnology Index | 12/19/2024 |
8 | SeaCrest Wealth Management LLC Has 427,000 Stake in iShares Biotechnology ETF | 01/17/2025 |
| In Threey Sharp Ratio | -0.36 |
IShares |
IShares Biotechnology Relative Risk vs. Return Landscape
If you would invest 14,279 in iShares Biotechnology ETF on November 2, 2024 and sell it today you would lose (392.00) from holding iShares Biotechnology ETF or give up 2.75% of portfolio value over 90 days. iShares Biotechnology ETF is generating negative expected returns assuming volatility of 1.2916% on return distribution over 90 days investment horizon. In other words, 11% of etfs are less volatile than IShares, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
IShares Biotechnology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IShares Biotechnology's investment risk. Standard deviation is the most common way to measure market volatility of etfs, such as iShares Biotechnology ETF, and traders can use it to determine the average amount a IShares Biotechnology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0295
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IBB |
Estimated Market Risk
| 1.29 actual daily | 11 89% of assets are more volatile |
Expected Return
| -0.04 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average IShares Biotechnology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IShares Biotechnology by adding IShares Biotechnology to a well-diversified portfolio.
IShares Biotechnology Fundamentals Growth
IShares Etf prices reflect investors' perceptions of the future prospects and financial health of IShares Biotechnology, and IShares Biotechnology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IShares Etf performance.
| Price To Earning | 3.16 X | |||
| Price To Book | 3.39 X | |||
| Price To Sales | 4.94 X | |||
| Earnings Per Share | (11.38) X | |||
| Total Asset | 7.41 B | |||
About IShares Biotechnology Performance
By analyzing IShares Biotechnology's fundamental ratios, stakeholders can gain valuable insights into IShares Biotechnology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if IShares Biotechnology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if IShares Biotechnology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
The fund generally will invest at least 80 percent of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. Nasdaq Biotechnology is traded on NASDAQ Exchange in the United States.| IShares Biotechnology generated a negative expected return over the last 90 days | |
| Latest headline from thelincolnianonline.com: SeaCrest Wealth Management LLC Has 427,000 Stake in iShares Biotechnology ETF | |
| The fund retains 99.93% of its assets under management (AUM) in equities |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Biotechnology ETF. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
The market value of iShares Biotechnology ETF is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is IShares Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Biotechnology's market value can be influenced by many factors that don't directly affect IShares Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.